Avastin® (bevacizumab), in combination with carboplatin and paclitaxel, is approved to treat advanced nonsquamous non–small cell lung cancer (nsNSCLC) in people who have not yet received chemotherapy for their advanced disease.
In a clinical study, it was shown that adding Avastin to carboplatin and paclitaxel (chemotherapy) can help people with advanced nsNSCLC:
See the table below for select side effects that increased by 2% or more in patients who added Avastin to carboplatin and paclitaxel (chemotherapy).
Talk to your doctor about the benefits and risks of Avastin. To learn about the possible side effects of taking Avastin, visit the Side Effects page.
Questions about Avastin treatment costs? Let us help you understand your financial assistance options.
Avastin is a tumor-starving therapy. Read more about how it's designed to work.
Find helpful information and support.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.